In the OVA-induced asthma mouse model, we found that the oral consumption of GM-080 at the sensitization phase could reduce anti-OVA specific IgE at low doses (Figure 6A) or anti-OVA specific IgG2a at low and high doses (Figure 6C) but did not change anti-OVA specific IgG1 levels (Figure 6B). This evidence concerns the gene IGHE and asthma.